NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy

May 16, 2019

|

Premium

NEW YORK (GenomeWeb) – An interim analysis of the National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) study — a precision medicine clinical trial for pediatric cancer — has found that 24 percent of participants are eligible to receive treatment with a targeted therapy, a match rate significantly higher than the 10 percent the researchers expected at the outset of the trial.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

Evaluation of the Oncomine BRCA Research Assay for Variant Detection by Next-Generation Sequencing

Quantitative Clonal Barcode Analysis

Next-Generation Cytogenetics: Bionano Whole Genome Mapping Resolves Structural Variants in Heterogeneous Cancer Samples

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

17

Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun

25

Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

Jun

26

Featured Webinar

Genome-Wide Study Reveals a Novel Regulatory Pathway: Translation Affects mRNA Stability in a Codon-Dependent Manner

This webinar will outline a study that combined genome-wide and classical molecular approaches to demonstrate that translation strongly affects mRNA stability in a codon-dependent manner, ultimately influencing mRNA and protein levels in higher organisms.

Menu